GlassScriptPhysician profile
Anna L Adams
NPI 1407949209
$4,429.70
in general payments reported to CMS, 2019-2025
27 companies · $865 in 2025
The $865 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $529 · 2022: $775 · 2023: $1,377 · 2024: $884 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,037 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,036.59 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,223.67 | 2021-2025 | Rinvoq, Skyrizi, Viberzi |
| Janssen Biotech, INC. | $472.98 | 2021-2025 | Stelara, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $418.57 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $307.62 | 2021-2024 | Entyvio, Gattex |
| Celgene Corporation | $291.25 | 2022-2024 | Zeposia |
| Mindray Ds USA, INC. | $245.77 | 2024-2025 | Na Electrode,Indirect,International, Patient Monitor |
| Intercept Pharmaceuticals, INC. | $243.98 | 2021-2024 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $146.33 | 2021-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $134.50 | 2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $134.17 | 2025 | Iqirvo |
| Qol Medical, LLC | $121.31 | 2024-2025 | Sucraid, Sucraid |
| Amgen INC. | $101.60 | 2024 | Evenity |
| Ardelyx, INC. | $86.92 | 2023-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $80.91 | 2025 | Tremfya |
| Genzyme Corporation | $63.81 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $61.35 | 2025 | Voquezna |
| Novo Nordisk INC | $52.31 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $47.66 | 2023-2024 | Dificid |
| Organon LLC | $32.50 | 2023-2025 | Renflexis, Hadlima |
| Nestle Healthcare Nutrition INC. | $30.14 | 2022 | |
| Braintree Laboratories, INC. | $28.03 | 2024 | Suflave |
| Ethicon US, LLC | $24.82 | 2022 | |
| Gilead Sciences, INC. | $18.06 | 2021 | |
| Evoke Pharma, INC. | $16.56 | 2022 | |
| Pfizer INC. | $16.42 | 2025 | |
| Fresenius Kabi USA, LLC | $15.93 | 2023 | Idacio |
| Kite Pharma, INC. | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.